A bill introduced by Rep. Earl L. "Buddy" Carter would ban PBMs’ use of spread pricing in Medicaid, among other reforms.

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

This lawsuit may look like a business dispute on the surface. But underneath, it’s about something much more important: the right of patients to receive personalized, affordable care.

Rural hospitals are facing growing cybersecurity threats and digital demands but often lack the resources to respond — a gap ...

Hospital M&A activity slowed quite a bit in the first half of 2025, with deal volume and transacted revenue falling sharply amid economic uncertainty and sweeping policy changes. While traditional ...

The Trump administration's healthcare policy changes from the gutting of medical research grants to changes on the CDC vaccine board were the focus of the discussion on the latest episode of the ...

Digital health funding held steady in the first half of 2025, with AI-focused startups capturing the majority of capital and driving rapid adoption among providers. The digital health space also saw ...

Employers are advocating for changes to the 340B Drug Pricing Program, arguing that it allows hospitals to "buy low and sell high" by purchasing discounted medications and charging insured ...

Novartis has come up short in its bid to expand its blockbuster drug Cosentyx to an autoimmune disease whose only biologic treatment options are an old Roche drug and the biosimilars that have ...

Brensocatib, a drug Insmed licensed from AstraZeneca, met the main goal of a Phase 3 test in non-cystic fibrosis bronchiectasis. Insmed plans to seek regulatory approvals in this indication while ...

Some hospitals are turning to AI to help manage declining revenue and financial pressure, but one expert says success depends on more than just buying new tech. Prashant Karamchandani of Chartis ...